ANXO PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 43.75 TWD | +1.51% |
|
-0.91% | -10.07% |
| Sales 2022 | 866M 26.79M 2.11B | Sales 2023 | 940M 29.07M 2.28B | Capitalization | 2.71B 83.75M 6.58B |
|---|---|---|---|---|---|
| Net income 2022 | -12M -371K -29.17M | Net income 2023 | 21M 649K 51.05M | EV / Sales 2022 | 2.39 x |
| Net Debt 2022 | 646M 19.97M 1.57B | Net Debt 2023 | 492M 15.23M 1.2B | EV / Sales 2023 | 3.4 x |
| P/E ratio 2022 |
-114
x | P/E ratio 2023 |
116
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
0.82% | Free-Float | 99% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.51% | ||
| 1 week | -0.91% | ||
| Current month | -1.24% | ||
| 1 month | -5.51% | ||
| 3 months | -4.48% | ||
| 6 months | -11.79% | ||
| Current year | -10.07% |
1 week
42.70
44.60
1 month
42.3545.70
Current year
42.3550.50
1 year
42.3577.20
3 years
16.3077.20
5 years
16.3077.20
10 years
16.3077.20
| Managers | Title | Age | Since |
|---|---|---|---|
Chih Hsien Chen
DFI | Director of Finance/CFO | - | 30/09/15 |
Lin Chuan Yan
BRD | Director/Board Member | - | 31/12/12 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chung Cheng Chen
BRD | Director/Board Member | - | 22/05/18 |
Kuang Yang Hsu
BRD | Director/Board Member | - | 22/05/18 |
Chien Chih Wang
CHM | Chairman | - | 31/12/12 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 19/06/24 | 43.75 | +1.51% | 35,898 |
| 18/06/24 | 43.1 | -0.12% | 55,120 |
| 17/06/24 | 43.15 | -3.14% | 87,233 |
| 14/06/24 | 44.55 | +1.02% | 71,429 |
| 13/06/24 | 44.1 | -0.11% | 15,810 |
End-of-day quote Taipei Exchange, June 18, 2024
More quotes
Anxo Pharmaceutical Co., Ltd is a Taiwan-based company engaged in the development and application of special pharmaceutical technology platforms and the development, manufacture and sale of special generic drugs. The Company is involved in the research and development of niche-type technology platforms and products with high-tech thresholds and high barriers to entry, as well as the provision of contract development and manufacturing organization (CDMO) services for pharmaceutical companies at home and abroad. The Companyâs main operating revenues are from the sale of products, technical services, as well as original equipment manufacturer (OEM) services.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -10.07% | 75.12M | |
| +52.93% | 803B | |
| +41.17% | 631B | |
| -7.08% | 351B | |
| +17.40% | 324B | |
| +10.58% | 303B | |
| +16.42% | 243B | |
| +2.21% | 228B | |
| +10.33% | 217B | |
| +6.24% | 164B |
- Stock Market
- Equities
- 6677 Stock
